[ET Net News Agency, 18 August 2017] WuXi Biologics (02269) said it entered into a
license agreement with Arcus Biosciences, Inc., a biotechnology company based in the
United States, in relation to, among others, the grant of exclusive license to certain
development and commercialization rights of the Antibody.
The WuXi Biologics Group's business partner, Harbin Gloria Pharmaceuticals Co., Ltd.
contracted the Group to discover and develop a novel anti-PD-1 antibody, namely, GLS-010.
Arcus was granted an exclusive license to certain development and commercialization
rights of the Antibody in North America, Europe, Japan and certain other territories. WuXi
Biologics and Gloria Pharmaceuticals will receive from Arcus upfront and milestone fees up
to an aggregate amount of US$816 million. Further, Arcus will pay tiered royalty fees
(ranged from high single-digit percentage to low double-digit percentage) on the net sales
of the Antibody products. Arcus plans on developing the Antibody as a combination product
with the other product candidates in its portfolio. WuXi Biologics and Arcus intend to
enter into an exclusive agreement in relation to the development and manufacturing of
Arcus's biologics portfolio for a term of three years, and WuXi Biologics will be
appointed as the exclusive manufacturer for the Antibody in the territories. (HL)
(c) 2017 ET Net Limited. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers